New Key Statistics Module, Z-Score and F-Score
NAS:TARS Key Ratios
| Market Cap $ M | 3,150.36 |
| Enterprise Value $ M | 2,773.43 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 106.36 |
| Price/Book | 8.96 |
| Price/Sales | 5.09 |
| Price/Free Cash Flow | 55.44 |
| Price/Owner Earnings | 140.21 |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 606.00 |
| EPS (TTM) $ | -1.09 |
| Beneish M-Score | -2.36 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 2.90 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -88.85 |
| EV-to-EBITDA | -96.05 |
| PEG | -- |
| Shares Outstanding M | 43.88 |
| Net Margin (%) | -7.67 |
| Operating Margin % | -8.01 |
| Pre-tax Margin (%) | -6.49 |
| Quick Ratio | 3.17 |
| Current Ratio | 3.20 |
| ROA % (ttm) | -8.35 |
| ROE % (ttm) | -13.61 |
| ROIC % (ttm) | -88.44 |
| Dividend Yield % | -- |
| Altman Z-Score | 7.69 |
TARS Number of Guru Trades
TARS Volume of Guru Trades
Gurus Latest Trades with NAS:TARS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:TARS is held by these investors
Total 1
Tarsus Pharmaceuticals Inc Insider Transactions
No Available Data
Guru Commentaries on NAS:TARS
2026 Q2
6a6237b88379628c04d2479f TimesSquare U.S. Small Cap Growth 2Q26 Commentary
What the manager wrote
Tarsus Pharmaceuticals, a commercial-stage company focused on eye care, declined -10% despite continued commercial progress for its demodex blepharitis treatment, XDEMVY. While actual script volume continues to track well above consensus, the stock contracted during the period as the market prematurely priced in a potential competitor that is years away and gated by an untested ocular-tolerability profile.
News about NAS:TARS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers